Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study
暂无分享，去创建一个
A. Dispenzieri | Kihyun Kim | E. Kastritis | G. Merlini | S. Schönland | J. Vermeulen | N. Tran | M. Minnema | G. Palladini | A. Wechalekar | V. Hungria | M. Cibeira | V. Sanchorawala | R. Comenzo | S. Gibbs | Kenshi Suzuki | M. Gatt | E. Libby | Jin Lu | S. Khaled | X. Qin | P. Mollee | J. Valent | C. Venner | S. Wong | Hans C. Lee | A. Jaccard | M. Rosenzweig | N. Bumma | M. Beksaç